Skip to Main Content

Paper Details

SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.
Clinical Infectious Diseases
37
2013
3TC, ABC, CD4, FTC, HDL, HIV, HIV-1, HIV-1 RNA, HIV-1 infected, LDL, RTV, TC, TDF, TG, VF, abacavir, cholesterol, emtricitabine, human immunodeficiency virus, lamivudine, low-density lipoproteins, nucleoside, nucleoside reverse transcriptase, patients, ritonavir, tenofovir, tenofovir disoproxil fumarate, triglycerides

Datasets

Release 1.2